Below is a list of 25 privately held biotechnology and pharmaceutical companies, ranked by the amount of nonpublic financing they have raised so far in 2013.
Each company is listed by total raised (with a breakdown of the amount for companies reporting two events this year), the type of financing, the date announced, the purpose of the financing as stated by companies, the financing leader, other firms involved in the financing with their status as new or existing investors noted where available, and footnotes offering details of the events.
The list does not include four companies that completed private financing events earlier this year and subsequently filed for initial public offerings during 2013: Opthotech, Intrexon, PTC Therapeutics, and Agios Pharmaceuticals. Nor does the list include BioMotiv, a drug development accelerator that raised a combined $66 million from investors in two fundraising events in August, since BioMotiv differs from the other listed biopharma companies, which work to generate their own discoveries for development, instead licensing early-stage technologies for development with oversight from its team of professionals and network of partners.
The combination private- IPO financings reflected the recovery in earnest of the initial public offering (IPO) market after nearly a decade of inactivity, especially during the 2007–09 recession and the glacially slow recovery that has followed. Nearly all financing events recorded by the companies were venture financing rounds raised through investment by new and/or existing investors. In some cases, those equity financings were combined with either debt financing that the companies said was related, or the conversion of debt to equity.